The Landscape of Targeted Therapies in TNBC
Triple negative breast cancer (TNBC) constitutes the most aggressive molecular subtype among breast tumors. Despite progress on the underlying tumor biology, clinical outcomes for TNBC unfortunately remain poor. The median overall survival for patients with metastatic TNBC is approximately eighteen...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-04-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/12/4/916 |
| _version_ | 1797571123617988608 |
|---|---|
| author | Elena Vagia Devalingam Mahalingam Massimo Cristofanilli |
| author_facet | Elena Vagia Devalingam Mahalingam Massimo Cristofanilli |
| author_sort | Elena Vagia |
| collection | DOAJ |
| description | Triple negative breast cancer (TNBC) constitutes the most aggressive molecular subtype among breast tumors. Despite progress on the underlying tumor biology, clinical outcomes for TNBC unfortunately remain poor. The median overall survival for patients with metastatic TNBC is approximately eighteen months. Chemotherapy is the mainstay of treatment while there is a growing body of evidence that targeted therapies may be on the horizon with poly-ADP-ribose polymerase (PARP) and immune check-point inhibitors already established in the treatment paradigm of TNBC. A large number of novel therapeutic agents are being evaluated for their efficacy in TNBC. As novel therapeutics are now incorporated into clinical practice, it is clear that tumor heterogeneity and clonal evolution can result to de novo or acquired treatment resistance. As precision medicine and next generation sequencing is part of cancer diagnostics, tailored treatment approaches based on the expression of molecular markers are currently being implemented in clinical practice and clinical trial design. The scope of this review is to highlight the most relevant current knowledge regarding underlying molecular profile of TNBC and its potential application in clinical practice. |
| first_indexed | 2024-03-10T20:35:47Z |
| format | Article |
| id | doaj.art-5c1292d32c284454b78b30e6cf3722a3 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T20:35:47Z |
| publishDate | 2020-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-5c1292d32c284454b78b30e6cf3722a32023-11-19T21:03:56ZengMDPI AGCancers2072-66942020-04-0112491610.3390/cancers12040916The Landscape of Targeted Therapies in TNBCElena Vagia0Devalingam Mahalingam1Massimo Cristofanilli2Division of Hematology Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USADivision of Hematology Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USADivision of Hematology Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USATriple negative breast cancer (TNBC) constitutes the most aggressive molecular subtype among breast tumors. Despite progress on the underlying tumor biology, clinical outcomes for TNBC unfortunately remain poor. The median overall survival for patients with metastatic TNBC is approximately eighteen months. Chemotherapy is the mainstay of treatment while there is a growing body of evidence that targeted therapies may be on the horizon with poly-ADP-ribose polymerase (PARP) and immune check-point inhibitors already established in the treatment paradigm of TNBC. A large number of novel therapeutic agents are being evaluated for their efficacy in TNBC. As novel therapeutics are now incorporated into clinical practice, it is clear that tumor heterogeneity and clonal evolution can result to de novo or acquired treatment resistance. As precision medicine and next generation sequencing is part of cancer diagnostics, tailored treatment approaches based on the expression of molecular markers are currently being implemented in clinical practice and clinical trial design. The scope of this review is to highlight the most relevant current knowledge regarding underlying molecular profile of TNBC and its potential application in clinical practice.https://www.mdpi.com/2072-6694/12/4/916triple negative breast cancermolecular profilingDNA damage repairtargeted treatmentpersonalized medicine |
| spellingShingle | Elena Vagia Devalingam Mahalingam Massimo Cristofanilli The Landscape of Targeted Therapies in TNBC Cancers triple negative breast cancer molecular profiling DNA damage repair targeted treatment personalized medicine |
| title | The Landscape of Targeted Therapies in TNBC |
| title_full | The Landscape of Targeted Therapies in TNBC |
| title_fullStr | The Landscape of Targeted Therapies in TNBC |
| title_full_unstemmed | The Landscape of Targeted Therapies in TNBC |
| title_short | The Landscape of Targeted Therapies in TNBC |
| title_sort | landscape of targeted therapies in tnbc |
| topic | triple negative breast cancer molecular profiling DNA damage repair targeted treatment personalized medicine |
| url | https://www.mdpi.com/2072-6694/12/4/916 |
| work_keys_str_mv | AT elenavagia thelandscapeoftargetedtherapiesintnbc AT devalingammahalingam thelandscapeoftargetedtherapiesintnbc AT massimocristofanilli thelandscapeoftargetedtherapiesintnbc AT elenavagia landscapeoftargetedtherapiesintnbc AT devalingammahalingam landscapeoftargetedtherapiesintnbc AT massimocristofanilli landscapeoftargetedtherapiesintnbc |